Leonidas Arvanitis, M.D.

(877) 460-4673
Leonidas Arvanitis, M.D.
Pathologist
Clinical Expertise
  • Digestive System Pathology
  • Neuropathology
  • Thoracic Pathology
Other Languages Spoken
Greek
Academic Appointments
  • Associate Clinical Professor, Department of Pathology

 

Location

Education & Experience

Board Certifications

  • Anatomical and Clinical Pathology, American Board of Pathology, MOC

  • Neuropathology, American Board of Pathology, MOC

Degrees

  • 2005, M.D., University of Thessaly, School of Medicine, Larissa, Greece

Fellowship

  • 2012-2014, Clinical Fellow in Neuropathology, University of Pittsburgh Medical Center, Pittsburgh, PA

  • 2005-2008, Pathology, University of Thessaly, School of Medicine, Larissa, Greece

Residency

  • 2008-2012, Anatomic and Clinical Pathology, Rush University Medical Center, Chicago, IL

Professional Experience

  • 2023-present, Associate Clinical Professor, Department of Pathology, City of Hope, Duarte, CA

  • 2017-2023, Assistant Clinical Professor, Department of Pathology, City of Hope, Duarte, CA

  • 2014-2017, Assistant Professor of Pathology, Director of Neuropathology and Autopsy Service, Rush University Medical Center, Chicago, IL

Publications

  • Wang L, Oill AT, Blanchard M, Wu M, Hibbard J, Sepulveda S, Peter L, Kilpatrick J, Munoz M, Stiller T, Shulkin N, Wagner J, Dolatabadi A, Nisis M, Shepphird J, Sanchez G, Lingaraju C, Manchanda M, Natri H, Kouakanou L, Sun G, Oliver-Cervantes C, Georges J, Aftabizadeh M, Forman S, Priceman S, Ressler J, Arvanitis L, Cotter J, D'Apuzzo M, Tamrazi B, Badie B, Davidson T, Banovich N, Brown C. Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis. Res Sq [Preprint]. 2023 Oct 23:rs.3.rs-3454977. doi: 10.21203/rs.3.rs-3454977/v1. PMID: 37961215; PMCID: PMC10635314.
  • Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Wheeler D, Arvanitis L, Pillai R, Afkhami M, Chen BT, Sattler M, Erhunmwunsee L, Massarelli E, Kulkarni P, Amini A, Armstrong B, Salgia R. Spatial Immune Tumor Microenvironment Analysis of KRAS Mutant Non-Small Cell Lung Cancer and Immune Checkpoint Inhibitor Treatment Outcome. (Submitted to NPJ Precision Oncology)
  • Dias E Silva D, Mambetsariev I, Fricke J, Babikian R, Dingal ST, Mazdisnian F, Badie B, Arvanitis L, Afkhami M, Villanova-Calero M, Salgia R. A novel HLA-DQB2-MET gene fusion variant in lung adenocarcinoma with prolonged response to Tepotinib: Case Report. (Submitted to Clinical Lung Cancer)
  • Carrillo-Ng H, Arvanitis L, Manoukian S, Arias-Stella JA. Metastatic Testicular Sex Cord Tumor Harboring a EWSR1::ATF1 Gene Fusion-A Case Report of a Novel Neoplasm: "Inflammatory and Nested Testicular Sex Cord Tumor". Int J Surg Pathol. 2023 Sep 16:10668969231195043
  • Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal S, Guo L, Warden C, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser W, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chou T, Roy S, Kulkarni P and Salgia R. Acquired resistance to KRAS G12C small molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 Oct 13;9(41):eade3816
  • Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, Ramisetty S, Yuan Y, Cho H; Wu X, Li A, Vohra M, Saladi SV, Wheeler D, Arvanitis L, Massarelli E, Kulkarni P, Zeng Y, Salgia R. Targeting ITGB4/SOX2-driven lung cancer stem cells using proteasome inhibitors. iScience. 2023 Jul 10;26(8):107302
  • Sayer MR, Mambetsariev I, Lu K, Wong CW, Duche A, Beutler R, Fricke J, Pharaon R, Arvanitis L, Eftekhari Z, Amini A, Koczywas M, Massarelli E, Roosan MR, Salgia R. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy. (Front. Oncol., Volume 13 – 2023, fonc.2023.1064169)
  • Zhang K, Sun T, Li W, Guo Y, Li A, Wu J, Arvanitis L, Raz DJ. Inhibition of USP7 upregulates USP22 through desuppression of transcriptional activity of SP1 in human cancer cells. Cell Commun Signal. 2023 Nov 9;21(1):319.
  • Zhao D, Li H, Mambetsariev I, Mirzapoiazova T, Chen C, Fricke J, Kulkarin P, Villaflor V, Arvanitis L, Hamilton S, Afkhami M, Oillai R, Armstrong B, Erhunmwunsee L, Massarelli E, Sattler M, Amini A, Salgia R. Clinical and Molecular Features of KRAS Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers 2022, 14(19), 4933
  • Sun T, Zhang K, Li W, Liu YZ, Pangeni RP, Arvanitis L, Raz DJ. Transcription Factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression. Cell Commun Signal 20, 147 (2022).
  • Kethireddy N, Arvanitis L, LoBello J, Woo Y, Szelinger S, Chao J. A Case Report of Immunotherapy-Resistant MSI-H Gastric Cancer with Significant Intrapatient Tumoral Heterogeneity Characterized by Histologic Dedifferentiation. J. Clin. Med. 2022, 11(12), 3413
  • Mambetsariev I*, Arvanitis L*, Fricke J, Pharaon R, Baroz AR, Afkhami M, Koczywas M, Massarelli E, Salgia R. Small Cell Lung Cancer Transformation Following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. J.Clin.Med. 2022, 11, 1429 *co-first author
  • Mirzapoiazova T, Xiao G, Mambetsariev B, Nasser MW, Miaou E, Singhal SS, Srivastava S, Mambetsariev I, Nelson MS, Nam A, Behal A, Arvanitis LD, Atri P, Müschen M, Tissot FLH, Miser J, Kovach JS, Sattler M, Batra SK, Kulkarni P, Salgia R. Protein phosphatase 2A as a therapeutic target in small cell lung cancer. Mol Cancer Ther. 2021 Jul 12:molcanther.0013.2021. doi: 10.1158/1535-7163.MCT-21-0013. Epub ahead of print. PMID: 34253596.
  • Roosan MR, Mambetsariev I, Pharaon R, Fricke J, Baroz AR, Chao J, Chen C, Nasser MW, Chirravuri-Venkata R, Jain M, Smith L, Yost SE, Reckamp KL, Pillai R, Arvanitis LD, Afkhami M, Wang EW, Chung V, Cristea M, Fakih M, Koczywas M, Massarelli E, Mortimer J, Yuan Y, Batra SK, Pal S, Salgia R. Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. Cancers (Basel). 2021 Jun 3;13(11):2776. doi: 10.3390/cancers13112776. PMID: 34204917; PMCID: PMC8199748.
  • Reckamp KL, McQuerry JA, Mambetsariev I, Pharaon R, Yost SE, Fricke J, Mirzapoiazova T, Pillai RK, Arvanitis L, Khan Z, Fakih M, Yuan Y, Koczywas M, Massarelli E, Kulkarni P, Pal SK, Sattler M, Bild A, Salgia R: Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Science OA 2020, 7:FSO662.